One Capital Management LLC Buys Shares of 44,291 Privia Health Group, Inc. $PRVA

One Capital Management LLC bought a new stake in Privia Health Group, Inc. (NASDAQ:PRVA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 44,291 shares of the company’s stock, valued at approximately $1,050,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PRVA. Hantz Financial Services Inc. grew its stake in Privia Health Group by 456.2% in the fourth quarter. Hantz Financial Services Inc. now owns 1,129 shares of the company’s stock valued at $27,000 after purchasing an additional 926 shares in the last quarter. Global Retirement Partners LLC grew its stake in Privia Health Group by 579.8% in the fourth quarter. Global Retirement Partners LLC now owns 1,584 shares of the company’s stock valued at $38,000 after purchasing an additional 1,351 shares in the last quarter. Canada Pension Plan Investment Board grew its stake in Privia Health Group by 48.0% in the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock valued at $85,000 after purchasing an additional 1,200 shares in the last quarter. GAMMA Investing LLC grew its stake in Privia Health Group by 198.5% in the fourth quarter. GAMMA Investing LLC now owns 4,314 shares of the company’s stock valued at $102,000 after purchasing an additional 2,869 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Privia Health Group in the second quarter valued at about $113,000. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Insider Activity at Privia Health Group

In related news, CEO Parth Mehrotra sold 15,647 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $22.64, for a total transaction of $354,248.08. Following the completion of the sale, the chief executive officer owned 434,357 shares in the company, valued at $9,833,842.48. This represents a 3.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Matthew Shawn Morris sold 1,017 shares of the stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $24.96, for a total value of $25,384.32. Following the sale, the director owned 68,188 shares of the company’s stock, valued at approximately $1,701,972.48. The trade was a 1.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 361,330 shares of company stock worth $8,172,284 in the last 90 days. 5.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PRVA has been the topic of a number of recent research reports. Barclays lowered their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Piper Sandler reiterated an “overweight” rating and set a $36.00 price target on shares of Privia Health Group in a research note on Thursday, February 26th. Citigroup decreased their price target on Privia Health Group from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Jefferies Financial Group reiterated a “buy” rating and set a $32.00 price target on shares of Privia Health Group in a research note on Thursday, February 26th. Finally, Weiss Ratings downgraded Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Privia Health Group currently has an average rating of “Moderate Buy” and an average target price of $31.15.

Privia Health Group Stock Performance

PRVA opened at $20.66 on Thursday. The company has a market cap of $2.60 billion, a PE ratio of 129.13, a price-to-earnings-growth ratio of 1.67 and a beta of 0.90. The stock has a 50-day moving average of $22.61 and a 200-day moving average of $23.00. Privia Health Group, Inc. has a 52-week low of $18.77 and a 52-week high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, May 7th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.11. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The firm had revenue of $603.85 million during the quarter, compared to the consensus estimate of $560.99 million. During the same quarter in the prior year, the company earned $0.22 EPS. The firm’s revenue for the quarter was up 25.8% compared to the same quarter last year. On average, research analysts predict that Privia Health Group, Inc. will post 0.32 earnings per share for the current year.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.